别名 CACH2、CACN2、CACNA1C + [10] |
简介 Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents (PubMed:8392192, PubMed:7737988, PubMed:9087614, PubMed:9013606, PubMed:9607315, PubMed:12176756, PubMed:17071743, PubMed:11741969, PubMed:8099908, PubMed:12181424, PubMed:29078335, PubMed:29742403, PubMed:16299511, PubMed:20953164, PubMed:15454078, PubMed:15863612, PubMed:17224476, PubMed:24728418, PubMed:26253506, PubMed:27218670, PubMed:23677916, PubMed:30023270, PubMed:30172029, PubMed:34163037). Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm (By similarity). Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm (PubMed:15454078, PubMed:15863612, PubMed:17224476, PubMed:24728418, PubMed:26253506). Required for normal contraction of smooth muscle cells in blood vessels and in the intestine. Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells (PubMed:28119464). Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group (Probable).
(Microbial infection) Acts as a receptor for Influenzavirus (PubMed:29779930). May play a critical role in allowing virus entry when sialylated and expressed on lung tissues (PubMed:29779930). |
作用机制 ADRA1拮抗剂 [+3] |
原研机构 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2009-07-01 |
作用机制 Cav1.2拮抗剂 [+1] |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期1995-01-01 |
靶点 |
作用机制 Cav1.2拮抗剂 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期1965-06-25 |
开始日期2024-04-15 |
申办/合作机构 山东盛迪医药有限公司初创企业 |
开始日期2023-11-19 |
申办/合作机构 |
开始日期2023-10-25 |
申办/合作机构 |